The NGS-based RNA-sequencing Market was valued at USD 3.92 Billion in 2024, and is projected to reach USD 10.05 Billion by 2030, rising at a CAGR of 17.30%. This growth is attributed to rising demand for precision medicine, advancements in sequencing technologies, and increasing applications in diagnostics, drug discovery, and disease research. Expanding bioinformatics capabilities and declining sequencing costs further support widespread market adoption.
The COVID-19 pandemic has accelerated the adoption of NGS-based RNA-sequencing owing to its critical role in understanding viral mutations, host response, and pathogen transcriptomics. The urgent need for advanced genomic tools in vaccine and therapeutic development highlighted the value of RNA-sequencing, driving rapid integration into research and public health efforts. This shift has reinforced its importance in infectious disease monitoring and preparedness.
In addition, advancements in high-throughput sequencing technologies have significantly enhanced the speed, accuracy, and scalability of RNA-sequencing. These innovations enable more comprehensive transcriptome profiling, reduce turnaround times, and lower costs, making NGS-based RNA sequencing more accessible for both research and clinical applications.
However, high initial costs associated with sequencing platforms and infrastructure, and ethical concerns surrounding genomic data usage are expected to hamper market growth. These challenges may limit adoption, particularly in resource-constrained settings and regions with stringent data privacy regulations.
This product will be delivered within 1-3 business days.
The COVID-19 pandemic has accelerated the adoption of NGS-based RNA-sequencing owing to its critical role in understanding viral mutations, host response, and pathogen transcriptomics. The urgent need for advanced genomic tools in vaccine and therapeutic development highlighted the value of RNA-sequencing, driving rapid integration into research and public health efforts. This shift has reinforced its importance in infectious disease monitoring and preparedness.
In addition, advancements in high-throughput sequencing technologies have significantly enhanced the speed, accuracy, and scalability of RNA-sequencing. These innovations enable more comprehensive transcriptome profiling, reduce turnaround times, and lower costs, making NGS-based RNA sequencing more accessible for both research and clinical applications.
However, high initial costs associated with sequencing platforms and infrastructure, and ethical concerns surrounding genomic data usage are expected to hamper market growth. These challenges may limit adoption, particularly in resource-constrained settings and regions with stringent data privacy regulations.
NGS-based RNA-sequencing Market Report Highlights
- Based on product and service, the consumables segment dominated with the largest revenue share of 58.12% in 2024, due to continuous advancements in reagent chemistry and the growing demand for quality, efficient sequencing kits. However, services are expected to grow at the fastest CAGR over the forecast period.
- Based on workflow, the sequencing segment held the largest market share in 2024, driven by increased adoption of advanced platforms offering faster turnaround and cost-effective processing. On the other hand, the data analysis segment is anticipated to witness the fastest CAGR of 18.49% over the forecast period.
- Based on application, the drug discovery & development segment holds the largest revenue share for application in 2024. This is attributed to the growing use of RNA-sequencing in identifying novel targets and accelerating therapeutic development. However, the clinical diagnostics segment is projected to grow at the highest CAGR over the forecast period.
- Based on end use, the pharmaceutical & biotechnology companies segment held the largest share in 2024. The growth is due to increased adoption of RNA-sequencing for biomarker discovery, clinical research, and personalized drug development. On the other hand, the hospitals & clinics segment is expected to register the fastest growth rate during the projected period.
- North America dominated the NGS-based RNA-sequencing market owing to factors such as advanced healthcare infrastructure, strong research funding, and high adoption of precision medicine and genomic technologies. Asia-Pacific is expected to grow at the fastest CAGR during the forecast period.
Why Should You Buy This Report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. NGS-based RNA-sequencing Market Variables, Trends & Scope
Chapter 4. NGS-based RNA-sequencing Market: Product & Service Estimates & Trend Analysis
Chapter 5. NGS-based RNA-sequencing Market: Workflow Estimates & Trend Analysis
Chapter 6. NGS-based RNA-sequencing Market: Application Estimates & Trend Analysis
Chapter 7. NGS-based RNA-sequencing Market: End Use Estimates & Trend Analysis
Chapter 8. NGS-based RNA-sequencing Market: Regional Estimates & Trend Analysis by Product & Service, Workflow, Application, and End Use
Chapter 9. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The companies profiled in this NGS-based RNA-sequencing market report include:- Illumina, Inc.
- Thermo Fisher Scientific Inc.
- Merck KGaA
- QIAGEN N.V.
- Pacific Biosciences of California, Inc.
- Oxford Nanopore Technologies Ltd.
- Agilent Technologies, Inc.
- BGI Group
- Roche Holding AG
- Revvity, Inc.
Methodology
LOADING...
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 120 |
Published | April 2025 |
Forecast Period | 2024 - 2030 |
Estimated Market Value ( USD | $ 3.92 Billion |
Forecasted Market Value ( USD | $ 10.05 Billion |
Compound Annual Growth Rate | 17.3% |
Regions Covered | Global |
No. of Companies Mentioned | 11 |